We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMERI.L Regulatory News (MERI)

  • There is currently no data for MERI

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Admission - First day of dealing

6 Nov 2018 07:00

RNS Number : 4115G
Merian Chrysalis Investment Co. Ltd
06 November 2018
 

The information contained in this announcement is restricted and is not for publication, release or distribution in the United States of America, any member state of the European Economic Area (other than the United Kingdom), Canada, Australia, Japan or the Republic of South Africa.

 

 

Merian Chrysalis Investment Company Limited

(the "Company")

 

First day of dealings

 

 

6 November 2018: Further to the announcement on 2 November 2018, Merian Chrysalis Investment Company Limited (the "Company") is pleased to announce that 100,000,000 Ordinary Shares will at 8.00 a.m. today be admitted to the premium segment of the Official List and to trading on the London Stock Exchange's Main Market for listed securities ("Admission"). The Ordinary Shares will trade under the ticker: MERI (ISIN: GG00BGJYPP46).

 

In addition, the Company is pleased to announce that, to provide certainty to investors, the Investment Manager has agreed to cap the Company's ongoing charge expense ratio1 at 0.85% for the next 12 months or until the NAV reaches £200 million, whichever occurs earlier. This fee structure will be subject to review at the end of the 12 month period.

 

The total number of Ordinary Shares in the Company in issue immediately following Admission is 100,000,000 each with equal voting rights. The total voting rights figure can be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify their interest in the Company under the Disclosure Guidance and Transparency Rules of the Financial Conduct Authority. On Admission the Directors will, in aggregate, hold 0.07% of the issued share capital of the Company. PDMR Notifications are set out at the bottom of this announcement.

 

1 The ongoing charges expense ratio is calculated as the percentage the Company's annual running costs (excluding transaction costs and performance fees (if any) but including the annual management fees) represents of its net asset value.

 

For further information please contact:

 

Media contacts:

Ged Brumby, Smithfield Consultants

020 3047 2527

Olivia Evans, Smithfield Consultants

020 3047 2531

Amelie Shepherd, Merian Global Investors

020 7332 8345

Global Co-ordinator, Joint Bookrunner, Sponsor and Financial Adviser:

Liberum

020 3100 2000

Gillian Martin, Andrew Davies, Christopher Britton, Louis Davies

Joint Bookrunner:

Zeus

020 3829 5000

John Goold, Rupert Woolfenden

Merian Global Investors:

MGI is a leading, independent, global asset management firm. It is focused on delivering strong investment performance and customer-focused investment solutions that result in positive long-term outcomes. The business had assets under management of £34.4 billion, as at 31 July 2018.

 

Further information on the Company can be found on its website at www.Merian.com/Chrysalis

 

The Company's LEI is: 213800F9SQ753JQHSW24

 

Save for expressions defined in this announcement, words and expressions defined in the Prospectus shall have the same meaning in this announcement.

 

Important Notice

 

This announcement has been issued by and is the sole responsibility of the Company. Liberum Capital Limited and Zeus Capital Limited, each of which are authorised and regulated by the Financial Conduct Authority in the United Kingdom, are acting only for the Company in connection with the matters described in this announcement and are not acting for or advising any other person, or treating any other person as its client, in relation thereto and will not be responsible for providing the regulatory protection afforded to clients of each of them or advice to any other person in relation to the matters contained herein. Neither Liberum, Zeus nor any of its or their respective affiliates, directors, officers, employees, advisers or agents accepts any responsibility or liability whatsoever for this announcement, its contents or otherwise in connection with it or any other information relating to the Company, whether written, oral or in a visual or electronic format.

 

This announcement may not be published, distributed or transmitted by any means or media, directly or indirectly, in whole or in part, in or into the United States. This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States. The securities mentioned herein have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the "US Securities Act") or with any securities regulatory authority of any state or other jurisdiction of the United States and will not be offered, sold, exercised, resold, transferred or delivered, directly or indirectly, in or into the United States or to, or for the account or benefit of, any US person (as defined under Regulation S under the US Securities Act). The Company has not been, and will not be, registered under the U.S. Investment Company Act of 1940, as amended.

 

Neither this announcement nor any copy of it may be: (i) taken or transmitted into or distributed in any member state of the European Economic Area (other than the United Kingdom), Canada, Australia or the Republic of South Africa or to any resident thereof, or (ii) taken or transmitted into or distributed in Japan or to any resident thereof. Any failure to comply with these restrictions may constitute a violation of the securities laws or the laws of any such jurisdiction. The distribution of this announcement in other jurisdictions may be restricted by law and the persons into whose possession this document comes should inform themselves about, and observe any such restrictions.

 

Notification of transactions of persons discharging managerial responsibilities and persons closely associated with them

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name:

Andrew Haining

2

Reason for the notification

a)

Position/status:

Director

b)

Initial notification /Amendment:

Initial

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Merian Chrysalis Investment Company Limited

b)

LEI

213800F9SQ753JQHSW24

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

Ordinary Shares of no par value

b)

Nature of the transaction

GG00BGJYPP46

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

£1.00

30,000

d)

Aggregated information

- Aggregated volume

- Price

- Total value

 

30,000

£1.00

£30,000.00

e)

Date of the transaction

6 November 2018

f)

Place of the transaction

London

 

Notification of transactions of persons discharging managerial responsibilities and persons closely associated with them

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name:

Stephen Coe

2

Reason for the notification

a)

Position/status:

Director

b)

Initial notification /Amendment:

Initial

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Merian Chrysalis Investment Company Limited

b)

LEI

213800F9SQ753JQHSW24

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

Ordinary Shares of no par value

b)

Nature of the transaction

GG00BGJYPP46

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

£1.00

25,000

d)

Aggregated information

- Aggregated volume

- Price

- Total value

 

25,000

£1.00

£25,000.00

e)

Date of the transaction

6 November 2018

f)

Place of the transaction

London

 

Notification of transactions of persons discharging managerial responsibilities and persons closely associated with them

 

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name:

Simon Holden

2

Reason for the notification

a)

Position/status:

Director

b)

Initial notification /Amendment:

Initial

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Merian Chrysalis Investment Company Limited

b)

LEI

213800F9SQ753JQHSW24

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Identification code

Ordinary Shares of no par value

b)

Nature of the transaction

GG00BGJYPP46

c)

Price(s) and volume(s)

 

Price(s)

Volume(s)

£1.00

15,000

d)

Aggregated information

- Aggregated volume

- Price

- Total value

 

15,000

£1.00

£15,000.00

e)

Date of the transaction

6 November 2018

f)

Place of the transaction

London

 

This announcement is made in accordance with the requirements of the EU Market Abuse Regulation ("MAR") and the Company confirms that the PDMR's notification obligations under MAR have also been satisfied.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCFKPDPFBDDCDK
Date   Source Headline
18th Dec 202012:18 pmRNSResults of Extraordinary General Meeting
17th Dec 20204:38 pmRNSDirector Declaration
11th Dec 20207:00 amRNSNet Asset Value(s)
27th Nov 20203:03 pmRNSDirector/PDMR Shareholding
27th Nov 20203:02 pmRNSDirector/PDMR Shareholding
25th Nov 20203:38 pmRNSProposed Change of Name
8th Oct 20204:23 pmRNSHolding(s) in Company
7th Oct 20207:00 amRNSResults of Capital Raise
6th Oct 202011:20 amRNSUpdate on Placing
1st Oct 20207:00 amRNSPortfolio Update
28th Sep 202010:07 amRNSPrimaryBid.com Offer
28th Sep 202010:00 amRNSProposed Placing of Equity
22nd Sep 20205:05 pmRNSHolding(s) in Company
16th Sep 20209:11 amRNSPortfolio Update
15th Sep 20208:58 amRNSPortfolio Update
11th Sep 20207:00 amRNSPortfolio Update
10th Sep 20204:41 pmRNSSecond Price Monitoring Extn
10th Sep 20204:36 pmRNSPrice Monitoring Extension
10th Sep 202012:07 pmRNSSecond Price Monitoring Extn
10th Sep 202012:02 pmRNSPrice Monitoring Extension
8th Sep 202012:07 pmRNSSecond Price Monitoring Extn
8th Sep 202012:02 pmRNSPrice Monitoring Extension
2nd Sep 202012:07 pmRNSSecond Price Monitoring Extn
2nd Sep 202012:02 pmRNSPrice Monitoring Extension
1st Sep 20207:00 amRNSNet Asset Value(s)
29th Jul 20207:00 amRNSPortfolio Update
20th Jul 20207:00 amRNSPortfolio Update
6th Jul 202012:31 pmRNSHolding(s) in Company
6th Jul 202012:28 pmRNSHolding(s) in Company
26th Jun 20207:00 amRNSInterim Accounts to 31 March 2020
23rd Jun 202012:08 pmRNSSecond Price Monitoring Extn
23rd Jun 202012:02 pmRNSPrice Monitoring Extension
22nd Jun 20204:41 pmRNSSecond Price Monitoring Extn
22nd Jun 20204:35 pmRNSPrice Monitoring Extension
27th May 20207:00 amRNSQuarterly NAV and COVID-19 Portfolio Update
13th May 202012:07 pmRNSSecond Price Monitoring Extn
13th May 202012:02 pmRNSPrice Monitoring Extension
13th May 20207:00 amRNSPortfolio Update
7th May 20204:40 pmRNSSecond Price Monitoring Extn
7th May 20204:35 pmRNSPrice Monitoring Extension
6th May 202012:08 pmRNSSecond Price Monitoring Extn
6th May 202012:02 pmRNSPrice Monitoring Extension
30th Apr 202012:02 pmRNSPrice Monitoring Extension
15th Apr 202012:08 pmRNSSecond Price Monitoring Extn
15th Apr 202012:02 pmRNSPrice Monitoring Extension
9th Apr 202012:07 pmRNSSecond Price Monitoring Extn
9th Apr 202012:03 pmRNSPrice Monitoring Extension
26th Mar 20207:00 amRNSStatement relating to COVID-19
20th Mar 20204:46 pmRNSSecond Price Monitoring Extn
20th Mar 20204:38 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.